In vivo photoacoustic imaging of breast cancer tumor with HER2-targeted nanodiamonds

被引:8
|
作者
Zhang, Ti [1 ]
Cui, Huizhong
Fang, Chia-Yi
Jo, Janggun
Yang, Xinmai
Chang, Huan-Cheng
Forrest, M. Laird [1 ]
机构
[1] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA
来源
关键词
Nanodiamond; Photoacoustic Imaging; Breast Cancer; HER2; GOLD; TOMOGRAPHY; NANOPARTICLES; DIAGNOSIS; RESONANCE; PEPTIDE;
D O I
10.1117/12.2027253
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Radiation-damaged nanodiamonds (NDs) are ideal optical contrast agents for photoacoustic (PA) imaging in biological tissues due to their good biocompatibility and high optical absorbance in the near-infrared (NIR) range. Acid treated NDs are oxidized to form carboxyl groups on the surface, functionalized with polyethylene glycol (PEG) and human epidermal growth factor receptor 2 (HER2) targeting ligand for breast cancer tumor imaging. Because of the specific binding of the ligand conjugated NDs to the HER2-overexpressing murine breast cancer cells (4T1.2 neu), the tumor tissues are significantly delineated from the surrounding normal tissue at wavelength of 820 nm under the PA imaging modality. Moreover, HER2 targeted NDs (HER2-PEG-NDs) result in higher accumulation in HER2 positive breast tumors as compared to non-targeted NDs after intravenous injection (i.v.). Longer retention time of HER-PEG-NDs is observed in HER2 overexpressing tumor model than that in negative tumor model (4T1.2). This demonstrates that targeting moiety conjugated NDs have great potential for the sensitive detection of cancer tumors and provide an attractive delivery strategy for anti-cancer drugs.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging
    Kanazaki, Kengo
    Sano, Kohei
    Makino, Akira
    Shimizu, Yoichi
    Yamauchi, Fumio
    Ogawa, Satoshi
    Ding, Ning
    Yano, Tetsuya
    Temma, Takashi
    Ono, Masahiro
    Saji, Hideo
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2015, 11 (08) : 2051 - 2060
  • [2] HER2-targeted Tumor immunotherapy
    Wei, Huafeng
    Guo, Yajun
    BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 325 - 325
  • [3] HER2-targeted therapies beyond breast cancer - an update
    Yoon, Jeesun
    Oh, Do-Youn
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (09) : 675 - 700
  • [4] Cardiac Complications of HER2-Targeted Therapies in Breast Cancer
    Addetia K.
    DeCara J.M.
    Current Treatment Options in Cardiovascular Medicine, 2016, 18 (6)
  • [5] HER2-targeted multimodal imaging of anaplastic thyroid cancer
    Wei, Weijun
    Jiang, Dawei
    Rosenkrans, Zachary T.
    Barnhart, Todd E.
    Engle, Jonathan W.
    Luo, Quanyong
    Cai, Weibo
    AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (11): : 2413 - 2427
  • [6] HER2-targeted multimodal imaging of anaplastic thyroid cancer
    Wei, Weijun
    Jiang, Dawei
    Ni, Dalong
    Kang, Lei
    Engle, Jonathan
    Cai, Weibo
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S417 - S418
  • [7] HER2-Targeted Multimodal Imaging of aplastic Thyroid Cancer
    Wei, Weijun
    Jiang, Dawei
    Rosenkrans, Zachary
    Ni, Dalong
    Engle, Jonathan
    Luo, Quan-Yong
    Cai, Weibo
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [8] HER2-targeted therapies — a role beyond breast cancer
    Do-Youn Oh
    Yung-Jue Bang
    Nature Reviews Clinical Oncology, 2020, 17 : 33 - 48
  • [9] HER2-targeted therapies - a role beyond breast cancer
    Oh, Do-Youn
    Bang, Yung-Jue
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (01) : 33 - 48
  • [10] Dual HER2-targeted approaches in HER2-positive breast cancer
    Ahn, Eugene R.
    Vogel, Charles L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 371 - 383